Consultation Document for Case Definitions: Adverse Events of Special Interest and Adverse Events Following Immunization during COVID-19 Vaccine Introduction
MetadataShow full item record
Other Language Versions
This consultation document lists and provides definitions of adverse events of special interest and adverse events following immunization for COVID-19 vaccines that can be used as a common language for reporting these events. The importance of standardizing definitions of adverse events and their guidelines is that this will allow for data comparability and will lead to a better understanding of the adverse event. COVID-19 vaccine safety surveillance will be of the utmost importance and will require collaboration by all stakeholders once a vaccine is introduced. Sharing data and information will be critical and thus criteria and definitions for events and clinical developments need to be standardized as part of the vaccine safety surveillance. Regarding post-vaccination adverse event surveillance, conventional vaccine safety surveillance and pharmacovigilance systems will need to adapt quickly to new surveillance techniques and ensure that post-vaccination safety and exposure information is collected and processed quickly. Clinical studies of vaccines that have received emergency authorization for use will require close follow-up by multiple stakeholders to ensure that use of these vaccines will continue to be as safe and effective in the field as in clinical trials.
This notice should be preserved along with the article's original URL.Attribution-NonCommercial-ShareAlike 3.0 IGO
Showing items related by title, author, creator and subject.
Surveillance of Events Supposedly Attributable to Vaccination or Immunization (ESAVI) Linked to the Pandemic Influenza (H1N1) 2009 Vaccine and Crisis Prevention: Field Guide Pan American Health Organization (Washington, D.C., PAHO, 2010)The prevention of infectious disease through immunization is one of the greatest achievements of public health. In spite of this undeniable success story, immunization is not immune from controversy surrounding the occurrence ...
Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews, 16 June 2020 Pan American Health Organization; Evidence and Intelligence for Action in Health (EIH) (Washington, D.C., PAHO, 2020-06-16)Take home message thus far: • We examined 24 therapeutic options thus far; currently, there is no evidence of any important benefit from any therapeutic option (though remdesivir is revealing promise as one option based ...
Análise do Sistema de Informação da Vigilância de Eventos Adversos Pós-Vacinação no Brasil, 2014 a 2016 Pacheco, Flávia Caselli; Domingues, Carla Magda Allan Santos; Maranhão, Ana Goretti Kalume; Carvalho, Sandra Maria Deotti; Teixeira, Antonia Maria da Silva; Braz, Rui Moreira; Rebelo, Renata Cristina Freitas; Guilhem, Dirce Bellezi (2018-01)[RESUMO]. Objetivo. Descrever as características das notificações de eventos adversos pós-vacinação (EAPV) no Sistema de Informação da Vigilância de EAPV (SI-EAPV) on-line nos primeiros 2 anos de operação do sistema. Método. ...